Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following BL-8040 Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following BL-8040 Update

BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia

May 4, 2015 7:00 AM EDT

BL-8040 remains safe and well tolerated at highest dose; continues to induce robust mobilization and leukemia cell death

Top-line results expected Q4 2015

JERUSALEM--(BUSINESS WIRE)-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today successful completion of the dose escalation stage of its ongoing Phase 2 study of BL-8040, and commencement of the expansion stage at the optimal dose of this novel treatment for acute myeloid leukemia (AML). Top-line results from the... More